Thus, our data adds to a growing body of evidence suggesting that a combination of steroid plus p38 inhibitor, on the background of standard bronchodilator therapy, could deliver increased clinical efficacy in severe COPD patients. This evidence concerns the gene MAPK14 and chronic obstructive pulmonary disease.